Show simple item record

Hijerarhija dokaza u tumačenju kliničkog značaja interakcija lekova

dc.creatorNikolić, Božana
dc.creatorSavić, Miroslav
dc.date.accessioned2019-09-02T11:32:13Z
dc.date.available2019-09-02T11:32:13Z
dc.date.issued2012
dc.identifier.issn0025-8105
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1834
dc.description.abstractIntroduction. Since drug interactions may result in serious adverse effects or failure of therapy, it is of huge importance that health professionals base their decisions about drug prescription, dispensing and administration on reliable research evidence, taking into account the hierarchy of data sources for evaluation. Clinical Significance of Potential Interactions - Information Sources. The sources of data regarding drug interactions are numerous, beginning with various drug reference books. However, they are far from uniformity in the way of choosing and presenting putative clinically relevant interactions. Clinical Significance of Potential Interactions - Interpretation of Information. The difficulties in interpretation of drug interactions are illustrated through the analysis of a published example involving assessment made by two different groups of health professionals. Systematic Evaluation of Drug-Drug Interaction. The potential for interactions is mainly investigated before marketing a drug. Generally, the in vitro, followed by in vivo studies are to be performed. The major metabolic pathways involved in the metabolism of a new molecular entity, as well as the potential of induction of human enzymes involved in drug metabolism are to be examined. In the field of interaction research it is possible to make use of the population pharmacokinetic studies as well as of the pharmacodynamic assessment, and also the postregistration monitoring of the reported adverse reactions and other literature data. Conclusion. In vitro and in vivo drug metabolism and transport studies should be conducted to elucidate the mechanisms and potential for drug-drug interactions. The assessment of their clinical significance should be based on well-defined and validated exposure-response data.en
dc.description.abstractS konstantnim povećanjem broja lekova i broja starijih pacijenata, kao i polifarmacijom pacijenata s teškim oboljenjima, povećava se rizik za interakcije lekova. Kako interakcije lekova za posledicu mogu imati ozbiljne neželjene efekte ili izostajanje terapijskog efekta, izuzetno je važno da zdravstveni stručnjaci odluke o propisivanju, izdavanju i primeni lekova zasnivaju na pouzdanim dokazima dobijenim u istraživanjima, poštujući hijerarhiju u njihovom vrednovanju. Generalno, sprovode se in vitro, a potom i in vivo studije. Istražuju se veliki metabolički putevi uključeni u metabolizam novog molekulskog entiteta, kao i potencijal indukcije humanih enzima uključenih u metabolizam lekova. Taj pristup uglavnom istražuje enzime citohroma P-450, a može biti primenjen i na metaboličke puteve koji uključuju druge enzime. Velik napredak u istraživanjima lek-lek interakcija bio je pristup za praćenje interakcija lekova i transportera za ksenobiotike. Interakcije je moguće istražiti i dodatnim studijama populacione farmakokinetike, kao i farmakodinamičkim praćenjima i postregistracionim monitoringom izveštavanih neželjenih reakcija i drugih informacija iz literature.sr
dc.publisherDruštvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad
dc.rightsopenAccess
dc.sourceMedicinski pregled
dc.subjectDrug Interactionsen
dc.subjectPolypharmacyen
dc.subjectDrug Therapyen
dc.subjectCombination + adverse effectsen
dc.subjectEvidence-Based Medicine + standardsen
dc.subjectAccess to Informationen
dc.subjectFollow-Up Studiesen
dc.subjectInterakcije lekovasr
dc.subjectPolifarmacijasr
dc.subjectKombinovana terapija + neželjeni efektisr
dc.subjectMedicina zasnovana na dokazima + standardisr
dc.subjectDostupnost informacijasr
dc.subjectStudije praćenjasr
dc.titleHierarchy of evidence in interpretation of clinical significance of drug interactionsen
dc.titleHijerarhija dokaza u tumačenju kliničkog značaja interakcija lekovasr
dc.typearticle
dc.rights.licenseARR
dcterms.abstractНиколић, Божана; Савић, Мирослав; Хијерархија доказа у тумачењу клиничког значаја интеракција лекова; Хијерархија доказа у тумачењу клиничког значаја интеракција лекова;
dc.citation.volume65
dc.citation.issue1-2
dc.citation.spage45
dc.citation.epage49
dc.citation.other65(1-2): 45-49
dc.citation.rankM51
dc.identifier.doi10.2298/MPNS1202045N
dc.identifier.scopus2-s2.0-84860620023
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/634/1832.pdf
dc.identifier.rcubconv_638
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record